Skip to main
CODX
CODX logo

Co-Diagnostics (CODX) Stock Forecast & Price Target

Co-Diagnostics (CODX) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Co-Diagnostics Inc is positioned favorably within the expanding market for respiratory infectious disease diagnostics, particularly in the Middle East, due to strategic investments in the region, notably from the Kingdom of Saudi Arabia. The company's partnership with Arabian Eagle Manufacturing to commercialize its Co-Dx technologies across 19 MENA nations demonstrates its commitment to enhancing access to affordable PCR testing, especially in areas with significant healthcare needs. Additionally, Co-Diagnostics is advancing its proprietary Co-Dx PCR platform through critical regulatory pathways, underscoring its potential for growth beyond tuberculosis and reinforcing a positive outlook for the company's future in the molecular diagnostics sector.

Bears say

Co-Diagnostics Inc. faces significant risks that contribute to a negative outlook on its stock, including the potential for failure in clinical evaluations and challenges in securing regulatory clearance for its instruments and tests in the U.S. The company reported a revenue of only $145,000 for the third quarter of 2025, alongside a substantial net loss of $5.9 million, equating to a loss of $0.16 per share. Additionally, there are concerns regarding the upcoming capital raise, which is expected to be more dilutive and possibly present less favorable terms than previous raises, further impacting shareholder value.

Co-Diagnostics (CODX) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Co-Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Co-Diagnostics (CODX) Forecast

Analysts have given Co-Diagnostics (CODX) a Buy based on their latest research and market trends.

According to 3 analysts, Co-Diagnostics (CODX) has a Buy consensus rating as of Dec 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Co-Diagnostics (CODX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.